Bon Natural Life Secures Major Distribution Deal with Merrill-Youli

Bon Natural Life ( (BON) ) has issued an update.

On May 26, 2025, Bon Natural Life’s subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd, entered into a 36-month sales distribution agreement with Tianjin Merrill-Youli Trading Co., Ltd. This agreement grants Merrill-Youli the right to market and sell Bon’s Ambroxide products in the Asia-Pacific region, targeting the industrial fabric fragrance sector. With a contract value of up to US$18 million, this partnership aims to leverage Merrill-Youli’s market presence to accelerate the adoption of Bon’s Ambroxide line, boosting sales and profits. Additionally, Bon has developed a biosynthetic alternative to Sclareol, enhancing production efficiency and profitability, and positioning the company to expand into the textile fragrance market.

Spark’s Take on BON Stock

According to Spark, TipRanks’ AI Analyst, BON is a Neutral.

Bon Natural Life’s stock score is primarily driven by its challenging financial performance, with declining revenues and profitability. The bearish technical indicators further contribute to the low score. Although the stock appears undervalued, this is overshadowed by significant operational and liquidity concerns. Investors should be cautious and look for improvements in revenue generation and cash flow before considering an investment.

To see Spark’s full report on BON stock, click here.

More about Bon Natural Life

Bon Natural Life Limited is a leading bio-ingredient solutions provider specializing in natural, health, and personal care industries. The company focuses on producing and distributing Ambroxide, a synthetic molecule used in perfumery and fabric fragrances, which serves as a cruelty-free alternative to natural ambergris.

Average Trading Volume: 3,946,910

Technical Sentiment Signal: Sell

Current Market Cap: $10.69M

See more data about BON stock on TipRanks’ Stock Analysis page.